Argonaut Manufacturing Services, a CDMO serving the biopharma and life sciences industries, has secured $45 million in financing to support its new drug product fill/finish expansion in Carlsbad, CA. Underway since early 2023, the expansion includes a new dedicated facility with a state-of-the-art isolator-based filling line that more than quadruples existing drug product fill/finish capacity and augments vial filling capabilities for pre-filled syringes and cartridges for clinical and commercial supply. Argonaut expects to have fully validated the facility and all equipment in 2025.
 
Argonaut’s FDA-registered facilities are compliant with 21 CFR parts 210, 211, and 820 and offer flexible and scalable services for a broad range of biopharmaceuticals including monoclonal antibodies, proteins, peptides, oligonucleotides, and small molecules. Additionally, Argonaut maintains an ISO 13485:2016 certification to produce drug-device combination products. Argonaut’s quality systems have been successfully audited by biopharma customers and global regulatory agencies including the FDA and PMDA.

The financing was led by NewVale Capital, a growth equity fund focused on pharmaceutical and life science services businesses, with participation from existing majority investor Telegraph Hill Partners, and other current investors.
 
Wayne Woodard, founder and CEO of Argonaut, said, “Argonaut is uniquely positioned to address the manufacturing challenges that biopharma innovators face related to sterile fill / finish of complex and high-value drug products. We remain laser focused on leveraging our experienced team’s commitment to flexibility and client satisfaction while prioritizing quality and compliance. The recent commitment from NewVale Capital and the continued support of Telegraph Hill Partners paves a straight path to capacity expansion and fulfillment of our mission to become the world’s best Drug Product Manufacturing solutions provider for our clients.”
 
“The recent consolidation in the aseptic fill/finish market has highlighted the need for additional capacity to ensure patients have uninterrupted access to critical life-saving and life-extending therapies,” said Chris Duffy, SVP/GM of Biopharma Services at Argonaut. “Our deep expertise in fill/finish, coupled with our planned expansion will help address this need for our clients and we remain ready to take on new projects.”